Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study.


Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
05 Jan 2024
Historique:
medline: 8 1 2024
pubmed: 8 1 2024
entrez: 8 1 2024
Statut: aheadofprint

Résumé

Becker muscular dystrophy (BMD) is a dystrophinopathy due to in-frame mutations in the dystrophin gene (DMD) which determines a reduction of dystrophin at muscle level. BMD has a wide spectrum of clinical variability with different degrees of disability. Studies of natural history are needed also in view of up-coming clinical trials. From an initial cohort of 32 BMD adult subjects, we present a detailed phenotypic characterization of 28 patients, then providing a description of their clinical natural history over the course of 12 months for 18 and 24 months for 13 of them. Each patient has been genetically characterized. Baseline, and 1-year and 2 years assessments included North Star Ambulatory Assessment (NSAA), timed function tests (time to climb and descend four stairs), 6-minute walk test (6MWT), Walton and Gardner-Medwin Scale and Medical Research Council (MRC) scale. Muscle magnetic resonance imaging (MRI) was acquired at baseline and in a subgroup of 9 patients after 24 months. Data on cardiac function (electrocardiogram, echocardiogram, and cardiac MRI) were also collected. Among the clinical heterogeneity, a more severe involvement is often observed in patients with 45-X del, with a disease progression over two years. The 6MWT appears sensitive to detect modification from baseline during follow up while no variation was observed by MRC testing. Muscle MRI of the lower limbs correlates with clinical parameters.Our study further highlights how the phenotypic variability of BMD adult patients makes it difficult to describe an uniform course and substantiates the need to identify predictive parameters and biomarkers to stratify patients.

Sections du résumé

BACKGROUND BACKGROUND
Becker muscular dystrophy (BMD) is a dystrophinopathy due to in-frame mutations in the dystrophin gene (DMD) which determines a reduction of dystrophin at muscle level. BMD has a wide spectrum of clinical variability with different degrees of disability. Studies of natural history are needed also in view of up-coming clinical trials.
OBJECTIVES OBJECTIVE
From an initial cohort of 32 BMD adult subjects, we present a detailed phenotypic characterization of 28 patients, then providing a description of their clinical natural history over the course of 12 months for 18 and 24 months for 13 of them.
METHODS METHODS
Each patient has been genetically characterized. Baseline, and 1-year and 2 years assessments included North Star Ambulatory Assessment (NSAA), timed function tests (time to climb and descend four stairs), 6-minute walk test (6MWT), Walton and Gardner-Medwin Scale and Medical Research Council (MRC) scale. Muscle magnetic resonance imaging (MRI) was acquired at baseline and in a subgroup of 9 patients after 24 months. Data on cardiac function (electrocardiogram, echocardiogram, and cardiac MRI) were also collected.
RESULTS AND CONCLUSIONS CONCLUSIONS
Among the clinical heterogeneity, a more severe involvement is often observed in patients with 45-X del, with a disease progression over two years. The 6MWT appears sensitive to detect modification from baseline during follow up while no variation was observed by MRC testing. Muscle MRI of the lower limbs correlates with clinical parameters.Our study further highlights how the phenotypic variability of BMD adult patients makes it difficult to describe an uniform course and substantiates the need to identify predictive parameters and biomarkers to stratify patients.

Identifiants

pubmed: 38189759
pii: JND221513
doi: 10.3233/JND-221513
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Giulia Ricci (G)

Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.

Alessandra Govoni (A)

Neuromuscular and Rare Disease Unit, La Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy.

Francesca Torri (F)

Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.

Guja Astrea (G)

Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.

Bianca Buchignani (B)

Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
Department of Translational Research and of New Surgical and Medical Technologies Pisa University, Pisa, Italy.

Gemma Marinella (G)

Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.

Roberta Battini (R)

Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Department of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.

Maria Laura Manca (ML)

Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Department of Mathematics, University of Pisa, Pisa, Italy.

Vincenzo Castiglione (V)

Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Alberto Giannoni (A)

Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Michele Emdin (M)

Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Gabriele Siciliano (G)

Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.

Classifications MeSH